Back to top
more

Athenex, Inc. (ATNX)

(Delayed Data from NSDQ)

$10.12 USD

10.12
252,235

+0.19 (1.91%)

Updated May 3, 2019 04:00 PM ET

After-Market: $10.09 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

After Plunging 25.6% in 4 Weeks, Here's Why the Trend Might Reverse for Athenex (ATNX)

by Zacks Equity Research

Athenex (ATNX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Athenex (ATNX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Athenex (ATNX) delivered earnings and revenue surprises of 19.51% and -0.65%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Athenex (ATNX) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Athenex (ATNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Athenex (ATNX) Skin Treatment Klisyri Gets Approval in Europe

by Zacks Equity Research

Athenex (ATNX) announces approval for its skin treatment drug, Klisyri, in Europe. The company's partner Almirall is set to handle the launch of the drug in the region.

Omeros' (OMER) BLA for Narsoplimab Gets Extended Review

by Zacks Equity Research

The FDA extends review period for Omeros' (OMER) BLA seeking approval of narsoplimab for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy. Stock down.

Agenus (AGEN) Soars on Global License Deal With Bristol-Myers

by Zacks Equity Research

Agenus (AGEN) inks a definitive agreement with Bristol-Myers, wherein it will grant license to its bispecific antibody program AGEN1777 and another undisclosed target, to the latter.

Bayer (BAYRY) Inks Deal to Develop Therapies for Eye Diseases

by Zacks Equity Research

Bayer (BAYRY) enters a strategic deal with FUJIFILM Cellular Dynamics and Opsis Therapeutics to discover and develop cell therapies for addressing eye diseases.

Athenex (ATNX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Athenex (ATNX) delivered earnings and revenue surprises of 27.03% and 110.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Athenex (ATNX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Athenex (ATNX) delivered earnings and revenue surprises of -26.19% and 11.65%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Athenex (ATNX) Gets FDA Approval for Skin Treatment Klisyri

by Zacks Equity Research

Athenex (ATNX) wins the FDA nod for Klisyri as a topical treatment of actinic keratosis on the face or scalp. The drug will be launched in the first quarter of 2021 in the United States.

Athenex (ATNX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Athenex (ATNX) delivered earnings and revenue surprises of 4.35% and 81.93%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Athenex (ATNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Athenex (ATNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Athenex's NDA for Breast Cancer Drug Gets Priority Review

by Zacks Equity Research

The FDA accepts Athenex's (ATNX) NDA for oral paclitaxel and encequidar, intended to treat metastatic breast cancer, under a priority review. The FDA's verdict is awaited on Feb 28, 2021. Stock up.

Athenex (ATNX) Catches Eye: Stock Jumps 9.1%

by Zacks Equity Research

Athenex (ATNX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Athenex (ATNX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Athenex (ATNX) delivered earnings and revenue surprises of -32.26% and 89.49%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Athenex (ATNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Athenex (ATNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

All You Need to Know About Athenex (ATNX) Rating Upgrade to Strong Buy

by Zacks Equity Research

Athenex (ATNX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Athenex (ATNX): Strong Industry, Solid Earnings Estimate Revisions

by Zacks Equity Research

Athenex (ATNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Athenex (ATNX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Athenex (ATNX) delivered earnings and revenue surprises of -14.29% and 46.90%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Athenex (ATNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Athenex (ATNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Athenex, Inc. (ATNX) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Athenex, Inc. (ATNX).

Athenex (ATNX) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Athenex (ATNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Athenex (ATNX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Athenex (ATNX) delivered earnings and revenue surprises of 44.00% and 185.15%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Moving Average Crossover Alert: Athenex

by Zacks Equity Research

Athenex, Inc. (ATNX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Are Options Traders Betting on a Big Move in Athenex (ATNX) Stock?

by Zacks Equity Research

Investors need to pay close attention to Athenex (ATNX) stock based on the movements in the options market lately.